Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Update

Hims & Hers Health, Inc. (NYSE:HIMS) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 52,120,000 shares, a growth of 21.3% from the December 15th total of 42,970,000 shares. Based on an average daily trading volume, of 16,430,000 shares, the short-interest ratio is currently 3.2 days. Approximately 29.4% of the shares of the stock are short sold.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 7,500 shares of the firm’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00. Following the sale, the insider now owns 193,980 shares in the company, valued at $4,306,356. This trade represents a 3.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 268,932 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,080,208 shares of company stock valued at $29,106,823. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently bought and sold shares of the company. Raleigh Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares during the period. GAMMA Investing LLC raised its holdings in Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares in the last quarter. Quest Partners LLC lifted its position in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares during the period. CWM LLC lifted its position in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the period. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 115.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock valued at $110,000 after buying an additional 2,442 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $0.14 during trading hours on Friday, hitting $27.80. The company had a trading volume of 18,842,443 shares, compared to its average volume of 10,492,087. The stock has a 50-day moving average price of $27.60 and a 200 day moving average price of $21.80. The company has a market capitalization of $6.07 billion, a PE ratio of 63.19 and a beta of 1.31. Hims & Hers Health has a 52 week low of $8.14 and a 52 week high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the firm posted ($0.04) EPS. The company’s revenue for the quarter was up 77.1% compared to the same quarter last year. Analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HIMS. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and upped their target price for the stock from $24.00 to $25.00 in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. BTIG Research started coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price target for the company. Finally, TD Cowen reiterated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.